Pharmacotherapy for Sexual Dysfunction in Women

Area of Science:

• Women's Health
• Sexual Medicine
• Psychiatry

Background:

• Female sexual dysfunction (FSD) encompasses several conditions, including hypoactive sexual desire disorder (HSDD), female sexual arousal disorder (FSAD), and genitopelvic pain/penetration disorder (GPPD).
• The conceptualization and diagnostic criteria for FSD within the DSM-5 have been a subject of controversy.

Purpose of the Study:

• To review the controversy surrounding the DSM-5 classification of FSD.
• To provide an overview of current treatment studies for HSDD, FSAD, and GPPD.

Main Methods:

• Review of recent literature on FSD diagnosis and treatment.
• Analysis of updates in pharmacological and non-pharmacological interventions.

Main Results:

• The DSM-5's consolidation of HSDD and FSAD into a single category may inaccurately represent these distinct conditions and impede treatment access.
• Recent advancements include updates on testosterone therapy, vaginal estrogen for genitourinary syndrome of menopause, and bremelanotide for HSDD.
• New technologies are emerging to improve treatment bioavailability and delivery.

Conclusions:

• The current DSM-5 approach to FSD may require re-evaluation to ensure accurate diagnosis and facilitate access to effective treatments.
• A comprehensive range of treatment options, including pharmacological, physiological, and psychological approaches, are available for women with FSD, tailored to individual needs.